Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Syros Pharmaceuticals Inc (0S90.BE)

Compare

0.1380

-0.0050

(-3.50%)

At close: 9:40:04 PM GMT+1

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

CAMBRIDGE, Mass., February 28, 2025--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market ("Nasdaq") and the deregistration of its common stock in order to terminate and suspend the Company’s reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").

Business Wire 55 minutes ago

SYRS
'We are back' Greek shipyards say after decades of pain

The sound of hammer blows and welding drifted from the Skaramangas Shipyard near Athens last month as workers repaired the bow of a large tanker, while other vessels waited to be fixed in a dry dock nearby. The activity marks a major turnaround for the shipyard: a year ago, following decades of on-off government ownership, it sat empty, an emblem of the lingering impact of Greece's devastating 2009-2018 debt crisis. "Now there is vitality again," said Theodoros Evagelou, who was sandblasting and painting vessels at the yard.

Reuters 10 days ago

SYRS
Kia starts series production of Syros in India

Over 10k pre-sales achieved so far for the small Kia SUV.

Just Auto last month

SYRS
South Africa’s Westfalia Fruit acquires Belgian avocado products maker Syros

Syros supplies products under its professional market brand Syros and consumer market brand Wonky.

Just Food last month

SYRS
Kia launches Syros compact SUV in India

Automaker claims it sets new standards in its segment.

Just Auto 2 months ago

SYRS
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

Zacks 3 months ago

SYRS

ALLO

ABBV
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed, higher-risk myelodysplastic syndrome patients with RARA gene overexpression, did not achieve its primary endpoint. The firm removed tamibarotene from its valuation and downgraded the shares. Published first on TheFly – the ultimate source for

TipRanks 3 months ago

SYRS
Syros stock craters after lead cancer therapy flops in Phase III trial

The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.

Clinical Trials Arena 3 months ago

SYRS
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

CAMBRIDGE, Mass., November 12, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Sy

Business Wire 3 months ago

SYRS
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals ( NASDAQ:SYRS ) Third Quarter 2024 Results Key Financial Results Net loss: US$6.40m (loss...

Simply Wall St. 3 months ago

SYRS
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...

Despite a revenue drop, Syros Pharmaceuticals Inc (SYRS) advances its promising pipeline with a pivotal trial and financial stability.

GuruFocus.com 3 months ago

SYRS
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

CAMBRIDGE, Mass., October 31, 2024--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update.

Business Wire 3 months ago

SYRS
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

CAMBRIDGE, Mass., October 24, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update.

Business Wire 4 months ago

SYRS
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...

Syros Pharmaceuticals Inc (SYRS) reports no revenue for Q2 2024 but emphasizes progress in tamibarotene trials and cost management.

GuruFocus.com 4 months ago

SYRS
Insider Spends US$161k Buying More Shares In Syros Pharmaceuticals

Investors who take an interest in Syros Pharmaceuticals, Inc. ( NASDAQ:SYRS ) should definitely note that the Chief...

Simply Wall St. 5 months ago

SYRS
Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is a biopharmaceutical company focused on the development of treatments for cancer and diseases caused by gene expression dysregulation. On the day of the transaction, shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) were priced at $1.61, valuing the company with a market cap of $42.094 million. Over the past year, Jason Haas has increased his holdings in Syros Pharmaceuticals Inc (NASDAQ:SYRS) by purchasing 100,000 shares, with no recorded sales of shares by the insider.

GuruFocus.com 5 months ago

SYRS
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)

On the date of the purchase, shares of Syros Pharmaceuticals Inc were priced at $1.61, leading to a market cap of approximately $42.094 million. According to GF Value, the stock is currently significantly overvalued, with a price-to-GF-Value ratio of 2.93.

GuruFocus.com 5 months ago

SYRS
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

CAMBRIDGE, Mass., August 27, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial at the Society of Hematologic Oncology (SOHO) Annual Meeting taking place September 4-7, in Houston, Texas. Additionally, Syros announced that company management will partici

Business Wire 5 months ago

SYRS
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

Zacks 6 months ago

SYRS

ABBV

TRDA
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Syros Pharmaceuticals (SYRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 6 months ago

SYRS

Performance Overview

Return	0S90.BE	S&P 500
YTD	-30.30%	+1.24%
1-Year	-97.92%	+17.45%
3-Year	-98.80%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Syros Pharmaceuticals Inc (0S90.BE)

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

'We are back' Greek shipyards say after decades of pain

Kia starts series production of Syros in India

South Africa’s Westfalia Fruit acquires Belgian avocado products maker Syros

Kia launches Syros compact SUV in India

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

Syros stock craters after lead cancer therapy flops in Phase III trial

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...

Insider Spends US$161k Buying More Shares In Syros Pharmaceuticals

Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)

Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Performance Overview